BioCentury
ARTICLE | Financial News

Celladon amends follow-on

August 8, 2014 2:14 AM UTC

Gene therapy play Celladon Corp. (NASDAQ:CLDN) said it now plans to sell 4 million shares in a follow-on. If sold at the company's close of $10.54 on Wednesday, before Celladon announced the amendment, the company would raise $42.6 million. Celladon proposed the offering last month. Credit Suisse; Jefferies; Stifel and Wedbush PacGrow are underwriters. In January, Celladon raised $44 million through the sale of 5.5 million shares at $8 in an IPO. Celladon's lead product Mydicar is in the Phase IIb CUPID 2 trial to treat advanced heart failure, with data expected in April 2015. The product is a recombinant adeno-associated viral (AAV) vector carrying the gene for sarcoplasmic reticulum ATPase Ca++ transporting cardiac muscle slow twitch 2 ( ATP2A2; SERCA2A) (see BioCentury Extra, Jan. 29). ...